Literature DB >> 1139859

Influence of acute viral hepatitis on phenytoin kinetics and protein binding.

T F Blaschke, P J Meffin, K L Melmon, M Rowland.   

Abstract

Patients with liver disease are thought to have abnormal responses to drugs metabolized by the liver, although supportive evidence is sparse. The influence of acute viral hepatitis on the pharmacokinetics and protein binding of phenytoin (DPH) was examined in 5 patients. A longitudinal study design was used so that each patient acted as his own control. DPH clearance was unaffected by acute viral hepatitits over theconcentration range studie, but the percentage of unboudn DPH increased by an average of nearly one-third during acute viral hepatitis. A small decline in serum albumin concentration and elevated serum bilirubin levels may be responsible for the alterations in protein bindig. These results indicate that acute inflammatory liver disease has complex and perhaps paradoxical effects on durg disposition. Clinical and laboratory observations including plasma durg concentrations, still provide the best means for adjusting dosage regimens in patients with fluctuating hepatic function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1139859     DOI: 10.1002/cpt1975176685

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 2.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 4.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

5.  Disposition of valproic acid in patients with liver disease.

Authors:  U Klotz; T Rapp; W A Müller
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

Review 6.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 8.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 9.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 10.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.